MVT-301
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About Microvascular Therapeutics
Microvascular Therapeutics is a clinical-stage biotech company leveraging a proprietary microbubble and nanobubble platform to transform ultrasound from a diagnostic imaging tool into a therapeutic modality. Its diversified pipeline targets significant unmet needs in cardiology, oncology, neurology, and ophthalmology, with its lead program, MVT-100, having completed Phase II trials. The company is led by a founder with a proven track record in ultrasound contrast agent development and commercialization, and it is advancing its programs through strategic partnerships and non-dilutive grant funding.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |